Literature DB >> 12748632

Aetiology: Koch's postulates fulfilled for SARS virus.

Ron A M Fouchier1, Thijs Kuiken, Martin Schutten, Geert van Amerongen, Gerard J J van Doornum, Bernadette G van den Hoogen, Malik Peiris, Wilina Lim, Klaus Stöhr, Albert D M E Osterhaus.   

Abstract

Entities:  

Mesh:

Year:  2003        PMID: 12748632      PMCID: PMC7095368          DOI: 10.1038/423240a

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


× No keyword cloud information.

Main

According to Koch's postulates, as modified by Rivers for viral diseases, six criteria are required to establish a virus as the cause of a disease[1]. The first three criteria — isolation of virus from diseased hosts, cultivation in host cells, and proof of filterability — have been met for SCV by several groups[2,3,4,5]. Moreover, of 96 individuals complying with the World Health Organization's definition of SARS[6] in Hong Kong, 86 (90%) yielded laboratory evidence of SCV infection. We have tested for the three remaining criteria: production of comparable disease in the original host species or a related one, re-isolation of the virus, and detection of a specific immune response to the virus. We inoculated two macaques with Vero-cell-cultured SCV isolated from a fatal SARS case, and monitored their clinical signs, virus excretion and antibody response. The animals were killed six days post-inoculation (d.p.i.), and we then carried out gross and histopathological examinations of them. Both SCV-inoculated macaques became lethargic from 3 d.p.i. onwards and developed a temporary skin rash, and one suffered respiratory distress from 4 d.p.i. onwards. The macaques excreted virus from the nose and throat at 2–6 d.p.i., as shown by polymerase chain reaction with reverse transcription (RT-PCR) and by virus isolation (see supplementary information). The isolated virus was identical to that inoculated, as shown by negative-contrast electron microscopy (Fig. 1a) and RT-PCR analysis. Seroconversion to SCV, as determined by indirect immunofluorescence assay using infected Vero cells, was demonstrated in two other SCV-infected macaques at 16 d.p.i.. The virus was also isolated from the faeces of one of these animals (see supplementary information).
Figure 1

SARS-associated coronavirus and associated lesions in macaque lungs.

a, Virus particles re-isolated from nasal swabs of infected macaques display typical coronavirus morphology. b, Diffuse alveolar damage in the lung; alveoli are flooded with highly proteinaceous fluid (arrowhead) that stains dark pink. c, Several syncytia (arrowheads) are present in the lumen of a bronchiole and surrounding alveoli. Original magnifications: a, ×200,000; b, ×150; c, ×100.

SARS-associated coronavirus and associated lesions in macaque lungs.

a, Virus particles re-isolated from nasal swabs of infected macaques display typical coronavirus morphology. b, Diffuse alveolar damage in the lung; alveoli are flooded with highly proteinaceous fluid (arrowhead) that stains dark pink. c, Several syncytia (arrowheads) are present in the lumen of a bronchiole and surrounding alveoli. Original magnifications: a, ×200,000; b, ×150; c, ×100. At gross necropsy, one macaque had severe multifocal pulmonary consolidation, and SCV infection was detected in lung tissue by RT-PCR and virus isolation. Histologically, both macaques had interstitial pneumonia of differing severity. The one with gross lesions had diffuse alveolar damage, marked by necrosis of alveolar and bronchiolar epithelium and flooding of alveolar lumina with proteinaceous fluid, admixed with fibrin, erythrocytes, alveolar macrophages and neutrophils (Fig. 1b). Occasional multinucleated cells (syncytia) were present in the lumen of bronchioles and alveoli (Fig. 1c). These lesions are indistinguishable from those in biopsied lung tissue and in autopsy material from SARS patients[5], including the presence of syncytia in alveolar lumina[4]. SCV thus fulfils all of Koch's postulates as the primary aetiological agent of SARS. This does not exclude the possibility that other pathogens, including human metapneumovirus (hMPV) and Chlamydia pneumoniae, may have exacerbated the disease in some SARS patients. However, these were not present in SCV-inoculated macaques (results not shown), were not found consistently in SARS patients, and do not usually cause the lesions associated with SARS. Moreover, lesions in macaques infected experimentally with hMPV isolated from a non-SARS individual[7] were limited to mild suppurative rhinitis and minimal erosion in conducting airways, and disease was not exacerbated in two SCV-infected macaques subsequently inoculated with hMPV (results not shown). Supplementary Table 1 (PDF 7 kb)
  4 in total

1.  Severe acute respiratory syndrome (SARS).

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2003-03-21

2.  Viruses and Koch's Postulates.

Authors:  T M Rivers
Journal:  J Bacteriol       Date:  1937-01       Impact factor: 3.490

3.  Coronavirus as a possible cause of severe acute respiratory syndrome.

Authors:  J S M Peiris; S T Lai; L L M Poon; Y Guan; L Y C Yam; W Lim; J Nicholls; W K S Yee; W W Yan; M T Cheung; V C C Cheng; K H Chan; D N C Tsang; R W H Yung; T K Ng; K Y Yuen
Journal:  Lancet       Date:  2003-04-19       Impact factor: 79.321

4.  A newly discovered human pneumovirus isolated from young children with respiratory tract disease.

Authors:  B G van den Hoogen; J C de Jong; J Groen; T Kuiken; R de Groot; R A Fouchier; A D Osterhaus
Journal:  Nat Med       Date:  2001-06       Impact factor: 53.440

  4 in total
  448 in total

1.  The virus hunter.

Authors:  Tony Sheldon
Journal:  BMJ       Date:  2003-10-25

Review 2.  SARS coronavirus: a new challenge for prevention and therapy.

Authors:  Kathryn V Holmes
Journal:  J Clin Invest       Date:  2003-06       Impact factor: 14.808

3.  Severe acute respiratory syndrome: private hospital in Singapore took effective control measures.

Authors:  S C Yeoh; E Lee; B W Lee; D L Goh
Journal:  BMJ       Date:  2003-06-21

Review 4.  Severe acute respiratory syndrome and its lesions in digestive system.

Authors:  Jian-Zhong Zhang
Journal:  World J Gastroenterol       Date:  2003-06       Impact factor: 5.742

5.  Antigenic cross-reactivity between the nucleocapsid protein of severe acute respiratory syndrome (SARS) coronavirus and polyclonal antisera of antigenic group I animal coronaviruses: implication for SARS diagnosis.

Authors:  Z F Sun; X J Meng
Journal:  J Clin Microbiol       Date:  2004-05       Impact factor: 5.948

6.  Evaluation of advanced reverse transcription-PCR assays and an alternative PCR target region for detection of severe acute respiratory syndrome-associated coronavirus.

Authors:  Christian Drosten; Lily-Lily Chiu; Marcus Panning; Hoe Nam Leong; Wolfgang Preiser; John S Tam; Stephan Günther; Stefanie Kramme; Petra Emmerich; Wooi Loon Ng; Herbert Schmitz; Evelyn S C Koay
Journal:  J Clin Microbiol       Date:  2004-05       Impact factor: 5.948

7.  Confronting SARS: a view from Hong Kong.

Authors:  J S M Peiris; Y Guan
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2004-07-29       Impact factor: 6.237

8.  Recombinant protein-based enzyme-linked immunosorbent assay and immunochromatographic tests for detection of immunoglobulin G antibodies to severe acute respiratory syndrome (SARS) coronavirus in SARS patients.

Authors:  Ming Guan; Hsiao Ying Chen; Shen Yun Foo; Yee-Joo Tan; Phuay-Yee Goh; Shock Hwa Wee
Journal:  Clin Diagn Lab Immunol       Date:  2004-03

9.  Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry.

Authors:  Graham Simmons; Jacqueline D Reeves; Andrew J Rennekamp; Sean M Amberg; Andrew J Piefer; Paul Bates
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-09       Impact factor: 11.205

10.  Severe acute respiratory syndrome coronavirus evades antiviral signaling: role of nsp1 and rational design of an attenuated strain.

Authors:  Marc G Wathelet; Melissa Orr; Matthew B Frieman; Ralph S Baric
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.